Key result
Mitral valve repair with CABG in patients with severe ischemic cardiomyopathy resulted in 0% early operative mortality and 14% late mortality at up to 3 years, with marked symptomatic improvement.
Why the study?
Does mitral valve repair combined with CABG improve survival and symptoms in patients with severe ischemic cardiomyopathy and mitral insufficiency?
Observational (n=21)
No
Does mitral valve repair combined with CABG improve survival and symptoms in patients with severe ischemic cardiomyopathy and mitral insufficiency?
Mitral valve repair with CABG can be performed safely in patients with severe ischemic cardiomyopathy, leading to marked symptomatic improvement despite no significant change in LV function.
Answers are grounded in this paper and cite their sources.
Does not yet support routine mitral repair plus CABG in severe ischemic cardiomyopathy; leaves open survival benefit pending controlled trials.
BACKGROUND: Patients with ischemic mitral valve insufficiency (MR) and poor left ventricular (LV) function present a high operative risk. Whether to repair or replace these valves is controversial, while some suggest that heart transplant offers a better solution. We investigated our early and late results in this difficult subset of patients. METHODS: Between 1993-1999,115 patients underwent mitral valve repair (MVR) in our department. Twenty-one patients had severe LV dysfunction with ejection fraction < 25%. Mean age was 60 years (range 45-81). Nineteen (90%) were in New York Heart Association (NYHA) Class IV, 7 (33%) underwent emergency surgery, 3 (14%) were in cardiogenic shock, and 2 (10%) were taken to the operating room under cardiopulmonary resuscitation. All underwent coronary artery bypass grafting (CABG) in addition to MVR, with a mean number of grafts 2.9 per patient. RESULTS: There were no early operative deaths. The average stay in intensive care was 5.9 days (range 1-52). There were three late deaths (14%). Follow-up evaluation up to 3 years showed marked improvement in clinical status. Twelve (67%) patients are in NYHA Class I-II, and three (17%) in Class III. Echocardiography revealed good function of the mitral valve in all, although overall LV function did not change significantly. CONCLUSION: (1) MVR in patients with severe ischemic cardiomyopathy can be accomplished with excellent results. (2) There is marked symptomatic improvement in these patients, even though LV function did not seem to be improved. (3) Long-term survival still needs to be defined.
No takes yet. Share an insight, caveat, or question.
Bitran et al. (2001) conducted an observational in Ischemic mitral valve insufficiency and severe LV dysfunction (n=21). Mitral valve repair and CABG was evaluated on Early operative mortality. Mitral valve repair with CABG in patients with severe ischemic cardiomyopathy resulted in 0% early operative mortality and 14% late mortality at up to 3 years, with marked symptomatic improvement.
Synapse has enriched 10 related papers. Consider them for comparative context: